Adyen to Power Payment Technology for Eli Lilly's LillyDirect Platform
Key Takeaways
- •Adyen has been chosen to provide payment technology services for LillyDirect, Eli Lilly's direct-to-consumer platform that delivers FDA-approved medicines with free home delivery.
- •Patients on LillyDirect will be able to pay using credit and debit cards, digital wallets including Apple Pay and Google Pay, and HSA/FSA cards.
- •Adyen's platform will contribute fraud prevention, reconciliation, analytics, and AI-powered Intelligent Payment Routing that automatically selects the most efficient U.S. debit network for each transaction.
- •LillyDirect launched in January 2024 and serves therapeutic areas including weight management, diabetes, and migraine.
- •The partnership expands Adyen's healthcare portfolio as competition intensifies to serve the growing volume of consumer-facing health transactions in the United States.

Adyen, the global financial technology platform, has been selected to provide payment technology services for LillyDirect, Eli Lilly's direct-to-consumer platform that offers patients access to Lilly's FDA-approved medicines with free home delivery.
Through the partnership, LillyDirect will utilize Adyen's platform to offer patients a range of flexible payment options, including credit and debit cards, digital wallets such as Apple Pay and Google Pay, and HSA/FSA (Health Savings Account/Flexible Spending Account) cards. The inclusion of HSA/FSA support reflects a specific need in healthcare payments, where patients increasingly use tax-advantaged accounts to manage out-of-pocket prescription costs.
Matthew Fanelli, Head of Health and Wellness at Adyen, commented on the collaboration: "The U.S. healthcare industry is undergoing a shift toward direct-to-consumer models, and simpler payment options can play a critical role in how patients experience new digital platforms. We are thrilled to continue to enable more options for consumers."
LillyDirect, launched by Indianapolis-based Eli Lilly and Company in January 2024, covers therapeutic areas including weight management, diabetes, and migraine. The platform is part of a broader trend of pharmaceutical companies establishing digital channels to connect patients directly with prescribed treatments, a model that gained momentum as telehealth and home-delivery pharmacy services expanded rapidly during the pandemic. The platform enables patients to access certain Lilly medications through a streamlined online ordering and home delivery process.
Adyen's platform will also contribute fraud prevention, reconciliation, and analytics capabilities designed to reduce friction during checkout while maintaining a secure end-to-end payment experience. The platform's scalability is intended to give LillyDirect a foundation to expand and enhance its payment options as patient needs evolve over time.
Transactions processed through Adyen will utilize the company's Intelligent Payment Routing, an AI-powered feature that automatically selects the most efficient U.S. debit network for each transaction. According to Adyen, this optimization occurs without requiring additional integration on the merchant side.
Adyen, headquartered in Amsterdam, provides a single platform that integrates payment processing, risk management, and data analysis across online, mobile, and in-store channels. The company serves a range of industries including retail, technology, travel, and healthcare. The LillyDirect partnership adds to Adyen's growing healthcare portfolio as the payments industry competes to serve the increasing volume of consumer-facing health transactions in the United States.